New combo shrinks liver tumors in hard-to-treat colorectal cancer
NCT ID NCT07024537
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a treatment for people with colorectal cancer that spread to the liver and had not responded to at least two prior therapies. The treatment combined a strong chemotherapy cocktail delivered directly to the liver (FOLFOXIRI via hepatic arterial infusion) with an oral targeted drug called fuquintinib. The goal was to see how many patients' tumors shrank significantly. 44 patients took part in this single-arm phase 2 trial.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China Hospital of Sichuan University
Chengdu, Sichuan, 610041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can delivering cancer drug directly to the liver shrink tumors?
- Peer power: could community education boost cancer screening?
- AI eye for colonoscopy: could software catch what doctors miss?
- One drop, many cancers? a rapid test aims to spot cancer signals in blood, urine, or saliva
- Could a smartphone photo of stool help detect colon cancer?
- Liver tumors targeted directly: old pump, new drug